FRA:PFE - Deutsche Boerse Ag - US7170811035 - Common Stock - Currency: EUR
FRA:PFE (3/4/2025, 3:32:37 PM)
24.53
+0.39 (+1.59%)
The current stock price of PFE.DE is 24.53 EUR. In the past month the price decreased by -0.97%. In the past year, price decreased by -0.69%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 67 | 760.43B | ||
LLY.DE | ELI LILLY & CO | 66.98 | 760.15B | ||
ZEG.DE | ASTRAZENECA PLC | 21.82 | 446.45B | ||
JNJ.DE | JOHNSON & JOHNSON | 16.81 | 372.31B | ||
1JNJ.MI | JOHNSON & JOHNSON | 16.61 | 367.98B | ||
NOV.DE | NOVO NORDISK A/S-B | 26.21 | 355.97B | ||
SNW.DE | SANOFI | 14.32 | 275.64B | ||
SAN.PA | SANOFI | 14.27 | 274.84B | ||
1SAN.MI | SANOFI | 14.19 | 273.18B | ||
6MK.DE | MERCK & CO. INC. | 12.64 | 224.82B | ||
1MRKX.MI | MERCK & CO. INC. | 12.47 | 221.79B | ||
1PFE.MI | PFIZER INC | 8.6 | 139.42B |
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 88,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK US
Employees: 88000
Company Website: https://www.pfizer.com/
Investor Relations: https://investors.pfizer.com
Phone: 12127332323
The current stock price of PFE.DE is 24.53 EUR. The price increased by 1.59% in the last trading session.
The exchange symbol of PFIZER INC is PFE and it is listed on the Deutsche Boerse Ag exchange.
PFE.DE stock is listed on the Deutsche Boerse Ag exchange.
27 analysts have analysed PFE.DE and the average price target is 29.49 EUR. This implies a price increase of 20.23% is expected in the next year compared to the current price of 24.53. Check the PFIZER INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PFIZER INC (PFE.DE) has a market capitalization of 139.02B EUR. This makes PFE.DE a Large Cap stock.
PFIZER INC (PFE.DE) currently has 88000 employees.
PFIZER INC (PFE.DE) has a support level at 24.02 and a resistance level at 24.79. Check the full technical report for a detailed analysis of PFE.DE support and resistance levels.
The Revenue of PFIZER INC (PFE.DE) is expected to decline by -0.04% in the next year. Check the estimates tab for more information on the PFE.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PFIZER INC (PFE.DE) has a dividend yield of 6.55%. The yearly dividend amount is currently 1.55. Check the full fundamental report for a detailed analysis of PFE.DE dividend history, reliability and sustainability.
PFIZER INC (PFE.DE) will report earnings on 2025-04-29, before the market open.
The PE ratio for PFIZER INC (PFE.DE) is 8.58. This is based on the reported non-GAAP earnings per share of 2.86 and the current share price of 24.53 EUR. Check the full fundamental report for a full analysis of the valuation metrics for PFE.DE.
ChartMill assigns a fundamental rating of 4 / 10 to PFE.DE. There are concerns on the financial health of PFE.DE while its profitability can be described as average.
Over the last trailing twelve months PFE.DE reported a non-GAAP Earnings per Share(EPS) of 2.86. The EPS increased by 69.95% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 12.62% | ||
ROA | 3.76% | ||
ROE | 9.11% | ||
Debt/Equity | 0.69 |
ChartMill assigns a Buy % Consensus number of 71% to PFE.DE. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of -4.06% and a revenue growth -0.04% for PFE.DE